{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17"],"submitter":["Morandi F"],"pubmed_abstract":["Background
Anti-GD2 monoclonal antibody effectively treats high-risk neuroblastoma (HR-NB) by recruiting NK cells for antibody-dependent cellular cytotoxicity (ADCC). We recently developed a cell product containing mature, cytotoxic γδ T and NK cells (GADEKILL), and its potential use as a novel immunotherapy for HR-NB has been investigated.Methods
The GADEKILL γδ T and NK cells were analyzed by flow cytometry for the expression of activating and inhibitory receptors and for cytotoxicity against NB, both with and without dinutuximab-β, at a 1:1 effector-to-target ratio. NB cell lines with high and low/absent GD2 expression, as well as patient-derived 3D tumor spheres, all GD2-expressing, were used as targets. Comparative analyses were performed between GADEKILL NK and purifi"],"journal":["Frontiers in immunology"],"pagination":["1755500"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12901508"],"repository":["biostudies-literature"],"pubmed_title":["The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing."],"pmcid":["PMC12901508"],"pubmed_authors":["Faraci M","Pastorino F","Brignole C","Giardino S","Della Lastra M","Ciampi E","Morandi F","Airoldi I"],"additional_accession":[]},"is_claimable":false,"name":"The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.","description":"Background
Anti-GD2 monoclonal antibody effectively treats high-risk neuroblastoma (HR-NB) by recruiting NK cells for antibody-dependent cellular cytotoxicity (ADCC). We recently developed a cell product containing mature, cytotoxic γδ T and NK cells (GADEKILL), and its potential use as a novel immunotherapy for HR-NB has been investigated.Methods
The GADEKILL γδ T and NK cells were analyzed by flow cytometry for the expression of activating and inhibitory receptors and for cytotoxicity against NB, both with and without dinutuximab-β, at a 1:1 effector-to-target ratio. NB cell lines with high and low/absent GD2 expression, as well as patient-derived 3D tumor spheres, all GD2-expressing, were used as targets. Comparative analyses were performed between GADEKILL NK and purifi","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026","modification":"2026-07-15T17:32:06.314Z","creation":"2026-07-07T03:09:47.943Z"},"accession":"S-EPMC12901508","cross_references":{"pubmed":["41694338"],"doi":["10.3389/fimmu.2026.1755500"]}}